Cell Therapeutics Inc (NASDAQ:CTIC) Shares Lose


Boston, MA – (Financialstrend) – 03/24/2014 – James A. Bianco, the chief Executive Officer of Cell Therapeutics Inc (NASDAQ:CTIC) sold-off 395,000 shares of the company stock in the transaction that was dated Friday, 21 March. This stock was offloaded at an average-price of $3.83, and the value of the total transaction was $1,512,850.00. Post completion of this sale, the CEO now directly-owns 2,402,794 shares of Cell Therapeutics Inc (NASDAQ:CTIC) stock, valued at around $9,202,701. This transaction was disclosed in the filing with the SEC.

In separate news, analysts at the Wallach Beth Capital firm have initiated coverage on Cell Therapeutics Inc (NASDAQ:CTIC) shares in the research note to investors. They have assigned a rating of “hold” and a price target of $4.50 on the stock. Cell Therapeutics Inc (NASDAQ:CTIC) last posted the company’s quarterly-earnings results on 4 March. It reported earnings per share of $0.08 for the quarter, which beat the average projection of $0.16 by $0.24.

Cell Therapeutics Inc (NASDAQ:CTIC) had revenue of $32.90M for the quarter, in comparison to the average projection of $1.26 million. In the same quarter of the previous year, Cell Therapeutics Inc (NASDAQ:CTIC) posted earnings per share of $0.19. Analysts project that Cell Therapeutics Inc (NASDAQ:CTIC) will post earnings per share of $-0.39 for the current financial year.

Cell Therapeutics Inc (NASDAQ:CTIC) is a company in the biopharmaceutical space that is focused on acquisition and development as well as the commercialization of much less-toxic ways to treat cancer. It is concentrating efforts on the treatments that effectively target blood-related cancers wherever there is an unmet-medical need. It is mainly focused on commercializing of PIXUVRI in the EU for multiplies relapsed/ refractory aggressive non- Hodgkin lymphoma & is conducting its Phase III clinical-trial of pacritinib in treating of myelofibrosis. PIXUVRI is the novel aza-anthracenedione-derivative that is also structurally related to anthracyclines & anthracenediones, but it does not appear to actually be associated with that same level of cardiotoxic-effects.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.